Gene-specific complementary DNA (cDNA) was prepared from miRNA by using reversing TaqMan microRNA RT-Kit, Cat number # 4366596, (Applied Biosystems, Foster City, CA, USA), according to the manufacturer’s instructions. miRNA expression for enrolled samples was quantified using TaqMan 2x universal master mix II Cat number # 4440043, (Applied Biosystems, Foster City, CA, USA) and TaqMan microRNA Assay Mix containing PCR primers and TaqMan probes for miR-150. MiR-16 was used as endogenous control for normalisation. Fluorescence was acquired and detected by ABI step one- Applied Biosystems. To determine miRNA relative expression, it was reported as fold change (ΔCt and ΔΔCt calculations).
The overall survival (OS) was calculated from the date of diagnosis to the date of death or last follow up visit. Disease-free survival was calculated from the date of complete remission to the date of relapse, death or last follow up visit.
The overall survival (OS) was calculated from the date of diagnosis to the date of death or last follow up visit. Disease-free survival was calculated from the date of complete remission to the date of relapse, death or last follow up visit.